Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 201.00
Bid: 199.20
Ask: 203.50
Change: 0.00 (0.00%)
Spread: 4.30 (2.159%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 201.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Mon, 13th Dec 2021 10:03

(Alliance News) - Oxford BioMedica PLC on Monday confirmed that it has signed a new licence and supply agreement with the US's Arcellx, while also extending its commercial supply contract with Novartis AG.

The new contract grants Maryland-based biotechnology firm Arcellx a non-exclusive licence to Oxford Biomedica's LentiVector platform for its application in select CAR-T programmes and puts in place a three-year clinical supply agreement.

Under the terms of the agreement, Oxford Biomedica will receive payments related to the development and manufacturing of lentiviral vectors for use in clinical trials with the deal also allowing for payments to the group for the manufacture and supply of lentiviral vectors for commercial use.

Separately, Oxford Biomedica extended its commercial supply agreement with Switzerland's Novartis for the manufacture of lentiviral vectors for several Novartis CAR-T products.

Under the terms of the updated agreement, the companies have extended the terms of the commercial supply agreement to the end of 2028, and Oxford Biomedica has regained the rights to its LentiVector platform relating to three CAR-T targets. The group now has the right to work with potential pharmaceutical and biotech partners other than Novartis across all CAR-T targets.

In addition, under the terms of the new deal Novartis has been granted additional flexibility in the ordering of GMP batches but will no longer have a minimum order commitment. This is expected to result in a mid-single digit million pound reduction in previously guided financial year 2021 revenue.

Oxford Biomedica Chief Executive Officer John Dawson commented: "We have enjoyed a strategic partnership with Novartis since 2014 and are excited to announce this updated supply agreement which provides both companies with greater flexibility in good manufacturing practice supply of vector for Kymriah and other pipeline products and allows us to react to the rapidly growing dynamics of the commercial CAR-T sector."

Shares in Oxford BioMedica were trading down 1.3% at 1,188.00 pence each in London on Monday morning.

By Will Paige; willpaige@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
5 Mar 2024 17:09

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
5 Mar 2024 16:22

Oxford Biomedica shares rise on post-acquisition guidance

(Sharecast News) - Shares in cell and gene therapy specialist Oxford Biomedica were jumping on Tuesday afternoon, after the company updated the market on its medium-term financial guidance.

Read more
5 Mar 2024 08:57

LONDON BROKER RATINGS: Barclays cuts Bank of Ireland to 'equal weight'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
5 Feb 2024 11:34

EnSilica hires new chief financial officer from Oxford Biomedica

(Alliance News) - EnSilica PLC on Monday said it has appointed a new chief financial officer, who will join the company and board in May.

Read more
29 Jan 2024 12:35

IN BRIEF: Institut Merieux ups stake in Oxford BioMedica toward 10%

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell therapy - Completes purchase of ABL Europe SAS from Institut Merieux SA, cementing the partnership between Oxford BioMedica and Institut Merieux. ABL is a cell and gene therapy contract development and manufacturing organization with facilities in Lyon and Strasbourg in France. For the EUR15 million acquisition, Oxford BioMedica will issue 3.1 million new shares to Lyon-based Institut Merieux at a price of 407.4 pence, well above its current market price. This is a 3.2% stake, and Institut Merieux already had 3.3%, giving it a total 6.5% holding. Oxford BioMedica says Institut Merieux intends to raise this to 10.0% by the end of the September.

Read more
7 Dec 2023 21:10

Oxford BioMedica posts optimistic outlook on uptick in contract value

(Alliance News) - Oxford BioMedica PLC on Thursday said it is on track to achieve its guidance for the year, amid an uptick in current contracted value and growth supported by new orders.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
4 Dec 2023 10:32

Oxford BioMedica buys ABL Europe for consideration of EUR15 million

(Alliance News) - Oxford BioMedica PLC on Monday said that it has entered a sale and purchase agreement with TSGH SAS for the acquisition of ABL Europe SAS.

Read more
20 Oct 2023 10:02

SMALL-CAP WINNERS & LOSERS: Record down as managed assets decline

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

Read more
18 Oct 2023 09:39

LONDON BROKER RATINGS: Citigroup cuts Wizz Air to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
27 Sep 2023 11:24

Director dealings: TUI, Oxford Biomedica board members linked to buys

(Sharecast News) - TUI was among those on the list of director buys on Wednesday after its chief executive officer purchased almost 50,000 shares.

Read more
22 Sep 2023 09:33

LONDON BROKER RATINGS: BoA likes Dowlais; JPMorgan cuts Phoenix Group

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
21 Sep 2023 09:40

SMALL-CAP WINNERS & LOSERS: DFS Furniture gains share of weak market

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

Read more
20 Sep 2023 12:21

Oxford BioMedica shares up, in talks to buy ABL Europe but loss widens

(Alliance News) - Oxford BioMedica PLC on Wednesday said loss widened in the first half of 2023 as revenue fell, while it noted being in exclusive talks to buy ABL Europe from Institut Merieux SA for EUR15 million.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.